RT Journal Article
SR Electronic
T1 Estimation of SARS-CoV-2 antibody prevalence through integration of serology and incidence data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.27.21254471
DO 10.1101/2021.03.27.21254471
A1 Liangliang Wang
A1 Joosung Min
A1 Renny Doig
A1 Lloyd T Elliott
A1 Caroline Colijn
YR 2021
UL http://medrxiv.org/content/early/2021/03/28/2021.03.27.21254471.abstract
AB Serology tests for SARS-CoV-2 provide a paradigm for estimating the number of individuals who have had infection in the past (including cases that are not detected by routine testing, which has varied over the course of the pandemic and between jurisdictions). Classical statistical approaches to such estimation do not incorporate case counts over time, and may be inaccurate due to uncertainty about the sensitivity and specificity of the serology test. In this work, we provide a joint Bayesian model for case counts and serological data, integrating uncertainty through priors on the sensitivity and specificity. We also model the Phases of the pandemic with exponential growth and decay. This model improves upon maximum likelihood estimates by conditioning on more data, and by taking into account the epidemiological trajectory. We apply our model to the greater Vancouver area, British Columbia, Canada with data acquired during Phase 1 of the pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was funded by Genome B.C.'s COVID-19 Rapid Response Funding Initiative (project code COV-142).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work involves data that have been made publicly available by the British Columbia Centre for Disease Control, and so no IRB approval or exemption is required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOpen source software reproducing our experiments are provided on GitHub. https://github.com/lell/serology